Meyers, F J <br/><br/>
Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Oct 2000 
 - 4167 p.  digital 
<br/><br/> Publication Type: Comment; Letter 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Carcinoma, Renal Cell--drug therapy<br/>Combined Modality Therapy--methods<br/>Granulocyte-Macrophage Colony-Stimulating Factor--therapeutic use<br/>Humans<br/>Immunotherapy--methods<br/>Interferon-alpha--therapeutic use<br/>Interleukin-2--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Melanoma--drug therapy